Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
PR Newswire•23/10/2026•16:05 ET
0
Key Highlights
- ➤Ifetroban generally well tolerated in 31 systemic sclerosis patients over 12 months
- ➤Ten placebo patients comprised the randomized Phase 2a ASSIST-SSc trial control group
- ➤No serious adverse event was deemed related to study drug during treatment
- ➤Cumberland will submit the clinical study report to the FDA
- ➤Biomarker and cardiac imaging analyses will guide further ifetroban development
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results PR Newswire
Ifetroban was well tolerated in patients with systemic sclerosis
Get started
Create a free account to read the full story.